Amgen Stock Rockets 3.19% as Analysts Back Strong Growth Prospects

Amgen Inc (AMGN) stock rose by 3.19% on August 19, driven by positive analyst momentum and a sector-wide rally in healthcare equities.

The company's strong second-quarter performance topped Wall Street expectations on both revenue and earnings per share, with broad-based strength across its portfolio resulting in double-digit sales growth for numerous products.

A key catalyst was the price target upgrade from Argus, which raised its valuation target while reiterating a Buy rating. Analysts highlighted robust volume expansion across commercialized therapies and significant growth potential from newly launched treatments, biosimilars, and pipeline developments.

Market sentiment was bolstered by sector-level capital flows, with investors rotating into defensive healthcare and biopharmaceutical leaders amid broader equity rebalancing.